1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Astellas Pharma said on August 28 that a combination therapy of its antibody drug conjugate Padcev (enfortumab vedotin) and Merck’s PD-1 inhibitor Keytruda (pembrolizumab) is now approved in Europe as a first-line therapy for advanced bladder cancer.The European Commission granted…
To read the full story
Related Article
- Padcev-Keytruda Nears EU Nod for 1st Line Bladder Cancer
July 30, 2024
- Padcev/Keytruda Accepted for Chinese Review for 1st Line Bladder Cancer Use
March 29, 2024
- Japan Awards Priority Review for Keytruda/Padcev in Bladder Cancer: Astellas
February 19, 2024
- Keytruda/Padcev Filed in Japan for 1st Line Bladder Cancer Treatment: MSD, Astellas
February 1, 2024
- Astellas/Pfizer Seeks 1st Line Bladder Cancer Use for Padcev/Keytruda in EU
January 30, 2024
- Padcev/Keytruda Combo Nabs FDA Nod for 1st Line Bladder Cancer
December 19, 2023
- Padcev/Keytruda Combo Gets FDA Priority Review for Bladder Cancer
December 4, 2023
- Padcev/Keytruda Combo Wins US Accelerated Nod for First-Line Bladder Cancer: Astellas
April 5, 2023
BUSINESS
- LTL Pharma Sees 30% Drop in Gaster Sales after New LLP Coverage Rollout
February 19, 2025
- CureApp’s Alcoholism Therapy App Approved in Japan
February 19, 2025
- Japan Approves Shionogi’s Therapy App for Pediatric ADHD
February 19, 2025
- Kyorin Nabs Japan Option for Cyrano’s Post-Viral Smell Loss Drug
February 19, 2025
- COVID Shot Kostaive Lands EU Approval, 1st Nod Outside Japan
February 19, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…